Loading…
Over-the-Counter Hearing Aid Act of 2017
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,805 other S bills in the 115th — cohort avg 41d
Over-the-Counter Hearing Aid Act of 2017 This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to categorize certain hearing aids as over-the-counter hearing aids and issue regulations regarding those hearing aids. The regulations for over-the-counter hearing aids must: (1) provide reasonable assurances of safety and efficacy; (2) establish output limits and labeling requirements; and (3) describe requirements for the sale of hearing aids in-person, by mail, or online, without a prescription. State and local governments may not establish or continue in effect requirements specifically applicable to hearing products that are not identical to FDA requirements and that restrict or interfere with the servicing or sale of over-the-counter hearing aids. The FDA must update and finalize its draft guidance on hearing products. The guidance must clarify which products are medical devices.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (19)
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2018 · fourth_quarter · Pharmacy
S. 204/H.R. 878 (Trickett Wendler Right to Try Act of 2017); authorizes the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with state law. S. 469/H.R. 1245 (Affordable and Safe Prescription Drug Importation Act); amends the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors. S. 670/H.R. 1652 (Over-the-Counter Hearing Aid Act of 2017); provides for the regulation of over-the-counter hearing aids. S. 297/H.R. 749 (Increasing Competition in Pharmaceuticals Act/Lower Drug Costs through Competition Act); amends the Federal Food, Drug, and Cosmetic Act to revise provisions regarding review and approval of generic drug applications or supplements to generic drug applications for drugs in some circumstances. S. 974/ H.R. 2212 (CREATES Act of 2017); alters the market for drugs and biological products by changing the requirements for generic and biosimilar versions of drugs and biological products. R. 5247 (Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018); with regard to liability issues. S. 2315 (Over-the-Counter Drug Safety, Innovation, and Reform Act); amends the Federal Food, Drug, and Cosmetic Act to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved new drug application. H.R. 5795/ H.R. 6082 (Overdose Prevention and Patient Safety Act); amends the Public Health Service Act to protect the confidentiality of substance use disorder patient records by restricting use of patient records in any civil action. H.R. 5176 (Preventing Overdoses While in Emergency Rooms Act of 2018); requires the Department of Health and Human Services to establish a grant program to: (1) develop protocols for discharging patients who are treated for a drug overdose, and (2) enhance the integration and coordination of postdischarge care and treatment options for individuals with a substance use disorder. H.R. 5197 (ALTO Act); requires and provides funds for, the Department of Health and Human Services to carry out a three-year demonstration program awarding grants to hospitals and emergency departments to develop, implement, enhance, or study alternative pain management protocols and treatments that promote limited use of opioids in emergency departments. H.R. 5009 (Jessie's Law); requires the Department of Health and Human Services (HHS) to develop and disseminate best practices for health care providers and state agencies regarding the display of a patient's history of opioid addiction in the patient's medical records. S. 2981 (Opioid Overdose Reduction Act of 2018); limits an individual's civil liability for harm caused by the emergency administration of an opioid overdose reversal drug (e.g., naloxone). S. 2680 (Opioid Crisis Response Act of 2018); comprehensive bill to address the opioid crisis. S. 2315 (Over-the-Counter Drug Safety, Innovation, and Reform Act); to clarify the regulatory framework with respect to certain nonprescrption drugs that are marketed without an approved new drug application. General lobbying with regard to the federal preemption of state causes of action involving medical device and drug manufacturers. General lobbying with regard to off label promotion of pharmaceutical products. General lobbying with regard to pharmaceutical drug advertising. General lobbying with regard to pharmaceutical price-gouging. General lobbying with regard to biosimilar naming and labeling. General lobbying with regard to updating generic drug labeling responsibilities. General lobbying with regard to opioid manufacturer liability. General lobbying with regard to opioid superfund and Medicare Secondary Payer issues. General lobbying with regard to OTC monograph federal preemption issues.
Client expense: $1,300,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC)
2018 · fourth_quarter · Health Issues
Supported H.R. 2550, the Medicare Telehealth Parity Act which would allow audiologists to be reimbursed by Medicare for services administered via telehealth. The Academy has met with congressional offices on the Access to Frontline Health Care Act (H.R. 2042). This legislation would allow for medical practitioners in certain fields to have some of their student loans covered by the Department of Health and Human Services in exchange for practicing for two years in federally-defined frontline shortage areas. AAA met with Congressional offices to learn about the possible viability of legislation that would expand Medicare to cover hearing aids and related services to hearing aids in the 116th Congress. AAA has engaged in efforts to educate legislators about the recommendations relative to implementation of the Over-the-Counter Hearing Aid Act (S.670, H.R. 1652), as put forth in a white paper co-authored by organizations representing audiologists and hearing aid dispensers. AAA also met with the Food and Drug Administration regarding recommendations related to labeling and specifications of the forthcoming over-the-counter hearing aids.
Client expense: $30,000 · Firm income: Not reported
2018 · fourth_quarter · Health Issues
Issues related to the Over-The-Counter Hearing Aid Act, S. 670 and H.R. 1652
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Pharmacy
S. 204/H.R. 878 (Trickett Wendler Right to Try Act of 2017); authorizes the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law. S. 469/H.R. 1245 (Affordable and Safe Prescription Drug Importation Act); amends the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors. S. 670/H.R. 1652 (Over-the-Counter Hearing Aid Act of 2017); provides for the regulation of over-the-counter hearing aids. S. 297/H.R. 749 (Increasing Competition in Pharmaceuticals Act/Lower Drug Costs through Competition Act); amends the Federal Food, Drug, and Cosmetic Act to revise provisions regarding review and approval of generic drug applications or supplements to generic drug applications for drugs in some circumstances. S. 974 (CREATES Act of 2017); alters the market for drugs and biological products by changing the requirements for generic and biosimilar versions of drugs and biological products. R. 5247 (Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018); with regard to liability issues. S. 2315 (Over-the-Counter Drug Safety, Innovation, and Reform Act); amends the Federal Food, Drug, and Cosmetic Act to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved new drug application. H.R. 5795/ H.R. 6082 (Overdose Prevention and Patient Safety Act); amends the Public Health Service Act to protect the confidentiality of substance use disorder patient records by restricting use of patient records in any civil action. H.R. 5176 (Preventing Overdoses While in Emergency Rooms Act of 2018); requires the Department of Health and Human Services to establish a grant program to: (1) develop protocols for discharging patients who are treated for a drug overdose, and (2) enhance the integration and coordination of postdischarge care and treatment options for individuals with a substance use disorder. H.R. 5197 (ALTO Act); requires and provides funds for, the Department of Health and Human Services to carry out a three-year demonstration program awarding grants to hospitals and emergency departments to develop, implement, enhance, or study alternative pain management protocols and treatments that promote limited use of opioids in emergency departments. H.R. 5009 (Jessie's Law); requires the Department of Health and Human Services (HHS) to develop and disseminate best practices for health care providers and state agencies regarding the display of a patient's history of opioid addiction in the patient's medical records. S. 2981 (Opioid Overdose Reduction Act of 2018); limits an individual's civil liability for harm caused by the emergency administration of an opioid overdose reversal drug (e.g., naloxone). S. 2680 (Opioid Crisis Response Act of 2018); comprehensive bill to address the opioid crisis. General lobbying with regard to the preemption of states causes of action involving medical device and drug manufacturers. General lobbying with regard to off label promotion of pharmaceutical products. General lobbying with regard to pharmaceutical drug advertising. General lobbying with regard to pharmaceutical price-gouging. General lobbying with regard to biosimilar naming and labeling. General lobbying with regard to updating generic drug labeling responsibilities. General lobbying with regard to opioid manufacturer liability. General lobbying with regard to opioid superfund and Medicare Secondary Payer issues. General lobbying with regard to OTC monograph preemption issues.
2018 · third_quarter · Pharmacy
S. 204/H.R. 878 (Trickett Wendler Right to Try Act of 2017); authorizes the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with state law. S. 469/H.R. 1245 (Affordable and Safe Prescription Drug Importation Act); amends the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors. S. 670/H.R. 1652 (Over-the-Counter Hearing Aid Act of 2017); provides for the regulation of over-the-counter hearing aids. S. 297/H.R. 749 (Increasing Competition in Pharmaceuticals Act/Lower Drug Costs through Competition Act); amends the Federal Food, Drug, and Cosmetic Act to revise provisions regarding review and approval of generic drug applications or supplements to generic drug applications for drugs in some circumstances. S. 974 (CREATES Act of 2017); alters the market for drugs and biological products by changing the requirements for generic and biosimilar versions of drugs and biological products. R. 5247 (Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018); with regard to liability issues. S. 2315 (Over-the-Counter Drug Safety, Innovation, and Reform Act); amends the Federal Food, Drug, and Cosmetic Act to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved new drug application. H.R. 5795/ H.R. 6082 (Overdose Prevention and Patient Safety Act); amends the Public Health Service Act to protect the confidentiality of substance use disorder patient records by restricting use of patient records in any civil action. H.R. 5176 (Preventing Overdoses While in Emergency Rooms Act of 2018); requires the Department of Health and Human Services to establish a grant program to: (1) develop protocols for discharging patients who are treated for a drug overdose, and (2) enhance the integration and coordination of postdischarge care and treatment options for individuals with a substance use disorder. H.R. 5197 (ALTO Act); requires and provides funds for, the Department of Health and Human Services to carry out a three-year demonstration program awarding grants to hospitals and emergency departments to develop, implement, enhance, or study alternative pain management protocols and treatments that promote limited use of opioids in emergency departments. H.R. 5009 (Jessie's Law); requires the Department of Health and Human Services (HHS) to develop and disseminate best practices for health care providers and state agencies regarding the display of a patient's history of opioid addiction in the patient's medical records. S. 2981 (Opioid Overdose Reduction Act of 2018); limits an individual's civil liability for harm caused by the emergency administration of an opioid overdose reversal drug (e.g., naloxone). S. 2680 (Opioid Crisis Response Act of 2018); comprehensive bill to address the opioid crisis. General lobbying with regard to the federal preemption of state causes of action involving medical device and drug manufacturers. General lobbying with regard to off label promotion of pharmaceutical products. General lobbying with regard to pharmaceutical drug advertising. General lobbying with regard to pharmaceutical price-gouging. General lobbying with regard to biosimilar naming and labeling. General lobbying with regard to updating generic drug labeling responsibilities. General lobbying with regard to opioid manufacturer liability. General lobbying with regard to opioid superfund and Medicare Secondary Payer issues. General lobbying with regard to OTC monograph federal preemption issues.
| Democratic |
| NH |
| Susan M. Collins | Republican | ME |
Government targets: Federal Communications Commission (FCC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Client expense: $1,430,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Client expense: $1,510,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC)
2018 · third_quarter · Health Issues
Supported H.R. 2550, the Medicare Telehealth Parity Act which would allow audiologists to be reimbursed by Medicare for services administered via telehealth. The Academy has met with congressional offices on the Access to Frontline Health Care Act (H.R. 2042). This legislation would allow for medical practitioners in certain fields to have some of their student loans covered by the Department of Health and Human Services in exchange for practicing for two years in federally-defined frontline shortage areas. AAA has engaged in efforts to educate legislators about the recommendations relative to implementation of the Over-the-Counter Hearing Aid Act (S.670, H.R. 1652), as put forth in a white paper co-authored by organizations representing audiologists and hearing aid dispensers.
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Health Issues
Issues related to the Over-The-Counter Hearing Aid Act, S. 670 and H.R. 1652
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Pharmacy
S. 204/H.R. 878 (Trickett Wendler Right to Try Act of 2017); authorizes the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law. S. 469/H.R. 1245 (Affordable and Safe Prescription Drug Importation Act); amends the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors. S. 670/H.R. 1652 (Over-the-Counter Hearing Aid Act of 2017); provides for the regulation of over-the-counter hearing aids. S. 297/H.R. 749 (Increasing Competition in Pharmaceuticals Act/Lower Drug Costs through Competition Act); amends the Federal Food, Drug, and Cosmetic Act to revise provisions regarding review and approval of generic drug applications or supplements to generic drug applications for drugs in some circumstances. S. 974 (CREATES Act of 2017); alters the market for drugs and biological products by changing the requirements for generic and biosimilar versions of drugs and biological products. R. 5247 (Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018); with regard to liability issues. S. 2315 (Over-the-Counter Drug Safety, Innovation, and Reform Act); amends the Federal Food, Drug, and Cosmetic Act to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved new drug application. H.R. 5795/ H.R. 6082 (Overdose Prevention and Patient Safety Act); amends the Public Health Service Act to protect the confidentiality of substance use disorder patient records by restricting use of patient records in any civil action. H.R. 5176 (Preventing Overdoses While in Emergency Rooms Act of 2018); requires the Department of Health and Human Services to establish a grant program to: (1) develop protocols for discharging patients who are treated for a drug overdose, and (2) enhance the integration and coordination of postdischarge care and treatment options for individuals with a substance use disorder. H.R. 5197 (ALTO Act); requires and provides funds for, the Department of Health and Human Services to carry out a three-year demonstration program awarding grants to hospitals and emergency departments to develop, implement, enhance, or study alternative pain management protocols and treatments that promote limited use of opioids in emergency departments. H.R. 5009 (Jessie's Law); requires the Department of Health and Human Services (HHS) to develop and disseminate best practices for health care providers and state agencies regarding the display of a patient's history of opioid addiction in the patient's medical records. S. 2981 (Opioid Overdose Reduction Act of 2018); limits an individual's civil liability for harm caused by the emergency administration of an opioid overdose reversal drug (e.g., naloxone). S. 2680 (Opioid Crisis Response Act of 2018); comprehensive bill to address the opioid crisis. General lobbying with regard to the preemption of states causes of action involving medical device and drug manufacturers. General lobbying with regard to off label promotion of pharmaceutical products. General lobbying with regard to pharmaceutical drug advertising. General lobbying with regard to pharmaceutical price-gouging. General lobbying with regard to biosimilar naming and labeling. General lobbying with regard to updating generic drug labeling responsibilities. General lobbying with regard to opioid manufacturer liability. General lobbying with regard to opioid superfund and Medicare Secondary Payer issues. General lobbying with regard to OTC monograph preemption issues.
Client expense: $1,430,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Health Issues
Issues related to the Over-The-Counter Hearing Aid Act, S. 670 and H.R. 1652
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Health Issues
H.R. 1289 - Dorothy I. Height and Whitney M. Young, Jr., Social Work Reinvestment Act S.870 Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 Public Law No: 115-119 (S.1028/H.R. 3759) RAISE Family Caregivers Act S. 1188/H.R.2535 - Lifespan Respite Care Reauthorization Act of 2017 S.670/H.R. 1652 - Over-the-Counter Hearing Aid Act H.R. 6 - SUPPORT for Patients and Communities Act H.R.3331 - To amend title XI of the Social Security Act to promote testing of incentive payments for behavioral health providers for adoption and use of certified electronic health record technology. S.1732 - Improving Access to Behavioral Health Information Technology Act S. 1905/ H.R.3931 - Excellence in Mental Health and Addiction Treatment Expansion Act S.1016/H.R. 2556 - CONNECT for Health Act of 2017 S.2120/H.R. 5034 - International Violence Against Women Act of 2017 S.2164/H.R.2953 - To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings. S.1334/H.R.2797 - Patient Choice and Quality Care Act of 2017 H.R.620 - ADA Education and Reform Act of 2017 S.Res.427 - A resolution supporting the goals and ideals of Social Work Month during March 2018 and World Social Work Day on March 20, 2018. H.Res.770 - Supporting the goals and ideals of Social Work Month during March 2018 and World Social Work Day on March 20, 2018. H.R.3713 - Geriatrics Workforce and Caregiver Enhancement Act S. 2456/H.R. 5311 - CARA 2.0 Act of 2018 S.2301/H.R. 4778- Behavioral Health Coverage Transparency Act of 2018 S. 1015/H.R.2345 - National Suicide Hotline Improvement Act of 2017 H.R.4704 - Nursing Home CARE Act S.2227/H.R. 5306 - EMPOWER Care Act S.2076/H.R. 4256 - BOLD Infrastructure for Alzheimer's Act S.2680 - Opioid Crisis Response Act of 2018 Improving Parity for Mental Health and Substance Use Disorder Coverage. H.R. 5942 - Health Equity and Accountability Act of 2018 Preserve ACA Essential Health Benefits, cost sharing subsidies, state waivers, and funding for navigators and assisters. Reduce Gun Violence: Comprehensive Legislative Solutions to firearm-related injuries and fatalities Opioid Epidemic 340B drug pricing issues Section 1115 waiver approval issues Medicare Part D program issues Medicaid non-emergency medical transportation (NEMT) issues
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2018 · first_quarter · Pharmacy
S. 204/H.R. 878 (Trickett Wendler Right to Try Act of 2017); authorizes the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law. S. 469/H.R. 1245 (Affordable and Safe Prescription Drug Importation Act); amends the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors. S. 670/H.R. 1652 (Over-the-Counter Hearing Aid Act of 2017); provides for the regulation of over-the-counter hearing aids. S. 297/H.R. 749 (Increasing Competition in Pharmaceuticals Act/Lower Drug Costs through Competition Act); amends the Federal Food, Drug, and Cosmetic Act to revise provisions regarding review and approval of generic drug applications or supplements to generic drug applications for drugs in some circumstances. S. 974 (CREATES Act of 2017); alters the market for drugs and biological products by changing the requirements for generic and biosimilar versions of drugs and biological products. General lobbying with regard to the preemption of states causes of action involving medical device and drug manufacturers. General lobbying with regard to off label promotion of pharmaceutical products. General lobbying with regard to pharmaceutical drug advertising. General lobbying with regard to pharmaceutical price-gouging. General lobbying with regard to biosimilar naming and labeling. General lobbying with regard to updating generic drug labeling responsibilities. General lobbying with regard to opioid manufacturer liability.
Client expense: $1,830,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Highway Traffic Safety Administration (NHTSA), SENATE, Transportation, Dept of (DOT)
2018 · first_quarter · Health Issues
H.R. 1652 Over-the-Counter Hearing Aid Act of 2017 S. 670 Over-the-Counter Hearing Aid Act of 2017
Client expense: $1,070,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Natl Highway Traffic Safety Administration (NHTSA), SENATE, Transportation, Dept of (DOT), U.S. Trade Representative (USTR), White House Office
2018 · first_quarter · Health Issues
"H.R. 1289 - Dorothy I. Height and Whitney M. Young, Jr., Social Work Reinvestment Act "S.870 Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 "Public Law No: 115-119 (S.1028/H.R. 3759) RAISE Family Caregivers Act "S. 1188/H.R.2535 - Lifespan Respite Care Reauthorization Act of 2017 "S.670/H.R. 1652 - Over-the-Counter Hearing Aid Act "H.R.3331 - To amend title XI of the Social Security Act to promote testing of incentive payments for behavioral health providers for adoption and use of certified electronic health record technology. "S.1732 - Improving Access to Behavioral Health Information Technology Act "S. 1905/ H.R.3931 - Excellence in Mental Health and Addiction Treatment Expansion Act "S.1016/H.R. 2556 - CONNECT for Health Act of 2017 "S.2120/H.R. 5034 - International Violence Against Women Act of 2017 "S.2164/H.R.2953 - To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings. "S.1334/H.R.2797 - Patient Choice and Quality Care Act of 2017 "H.R.620 - ADA Education and Reform Act of 2017 "S.Res.427 - A resolution supporting the goals and ideals of Social Work Month during March 2018 and World Social Work Day on March 20, 2018. "H.Res.770 - Supporting the goals and ideals of Social Work Month during March 2018 and World Social Work Day on March 20, 2018. "H.R.3713 - Geriatrics Workforce and Caregiver Enhancement Act "S. 2456/H.R. 5311 - CARA 2.0 Act of 2018 "S.2301/H.R. 4778- Behavioral Health Coverage Transparency Act of 2018 "S. 1015/H.R.2345 - National Suicide Hotline Improvement Act of 2017 "H.R.4704 - Nursing Home CARE Act "S.2227/H.R. 5306 - EMPOWER Care Act "S.2076/H.R. 4256 - BOLD Infrastructure for Alzheimer's Act "Improving Parity for Mental Health and Substance Use Disorder Coverage. "Preserve ACA Essential Health Benefits, cost sharing subsidies, state waivers, and funding for navigators and assisters. "Reduce Gun Violence: Comprehensive Legislative Solutions to firearm-related injuries and fatalities "Opioid Epidemic
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2018 · first_quarter · Health Issues
Issues related to the Over-The-Counter Hearing Aid Act, S. 670 and H.R. 1652
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · fourth_quarter · Health Issues
H.R. 1652 Over-the-Counter Hearing Aid Act of 2017 S. 670 Over-the-Counter Hearing Aid Act of 2017
Client expense: $1,200,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Natl Highway Traffic Safety Administration (NHTSA), SENATE, Transportation, Dept of (DOT), U.S. Trade Representative (USTR), White House Office
2017 · fourth_quarter · Pharmacy
S. 204/H.R. 878 (Trickett Wendler Right to Try Act of 2017); authorizes the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law. S. 469/H.R. 1245 (Affordable and Safe Prescription Drug Importation Act); amends the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors. S. 670/H.R. 1652 (Over-the-Counter Hearing Aid Act of 2017); provides for the regulation of over-the-counter hearing aids. S. 297/H.R. 749 (Increasing Competition in Pharmaceuticals Act/Lower Drug Costs through Competition Act); amends the Federal Food, Drug, and Cosmetic Act to revise provisions regarding review and approval of generic drug applications or supplements to generic drug applications for drugs in some circumstances. S. 974 (CREATES Act of 2017); alters the market for drugs and biological products by changing the requirements for generic and biosimilar versions of drugs and biological products. General lobbying with regard to the preemption of states causes of action involving medical device and drug manufacturers. General lobbying with regard to off label promotion of pharmaceutical products. General lobbying with regard to pharmaceutical drug advertising. General lobbying with regard to pharmaceutical price-gouging. General lobbying with regard to biosimilar naming and labeling. General lobbying with regard to updating generic drug labeling responsibilities.
Client expense: $1,420,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · fourth_quarter · Health Issues
Comments to HHS' Office for Human Research Protections on finalization of the rule on the Federal Policy for the Protection for Human Subjects; including: single IRB review mandate, revisions to the Common Rules informed consent requirements, and numerous other modifications. Comments to the Food and Drug Administration (FDA) Re: Docket Number FDA-2016-D-3466; Immediately in Effect Guidance Document: Conditions for Sale for Air Conduction Hearing Aids. Federal "Truth-in-Advertising" legislation; in general. Issues pertaining to scope of practice; in general. Repeal of the Affordable Care Act; in general. Comments to the Food and Drug Administration re: Docket No. FDA-2016-D-2268 for Insanitary Conditions at Compounding Facilities Comments to the Food and Drug Administration re: Docket 2014-D-1525-0358; Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application; Revised Draft Guidance For Industry. H.R.1652/S. 670, the "Over-the-Counter Hearing Aid Act of 2017," all provisions. H.R. 2430, the "FDA Reauthorization Act of 2017," provisions relating to the over-the-counter sale of hearing aids. Comments to the Federal Trade Commission Re: Notice of Workshop and Requesting Public Comments; Hearing Health and Technology - Workshop, Project No. P171200. Concerns regarding the potential impact of a revised United States Pharmacopeia (USP) Chapter 797 on physician practices and patient access to critical sterile drug products. H.R.1628 - American Health Care Act of 2017; in general. The "Better Care Reconciliation Act"; in general. Support for the nomination and confirmation of Jerome Adams, MD, to serve as the United States Surgeon General. H.R.3928, the "Truth in Healthcare Marketing Act of 2017;" all provisions.
Client expense: $190,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Housing & Urban Development, Dept of (HUD), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
2017 · fourth_quarter · Health Issues
Supported the Early Hearing Detection and Intervention Act (H.R. 1539, S. 562), a bill that proposes to amend the Public Health Service Act to reauthorize a program for early detection, diagnosis, and treatment regarding deaf and hard-of-hearing newborns, infants, and young children. Met with the FDA to discuss the potential regulations that would be promulgated from the Over-the-Counter Hearing Aid Act (S. 670, H.R. 1652) and the Medical Device User Fee Amendments (S. 934, H.R. 2430). This legislation authorized the FDA to create a category of hearing aids available over the counter for individuals who perceive that they have mild-to-moderate hearing loss. Supported H.R. 2550, the Medicare Telehealth Parity Act which would allow audiologists to be reimbursed by Medicare for services administered via telehealth. The Academy has met with congressional offices on the Access to Frontline Health Care Act (H.R. 2042). This legislation would allow for medical practitioners in certain fields to have some of their student loans covered by the Department of Health and Human Services in exchange for practicing for two years in federally-defined frontline shortage areas.
Client expense: $25,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2017 · fourth_quarter · Health Issues
Regulation of hearing aids; S. 670; H.R. 1652.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · fourth_quarter · Health Issues
Issues related to the Over-The-Counter Hearing Aid Act, S. 670 and H.R. 1652
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · fourth_quarter · Health Issues
Alexander-Murray Bipartisan Health Care Stabilization Act of 2017 S.1835 - Lower Premiums Through Reinsurance Act of 2017 Graham-Cassidy-Heller-Johnson Amendment in the nature of a substitute to HR 1628 - American Health Care Act of 2017 H.R.1628 - American Health Care Act of 2017 Better Care Reconciliation Act Discussion Draft ACA Repeal and Replace Proposals H.R. 1289 - Dorothy I. Height and Whitney M. Young, Jr., Social Work Reinvestment Act S.870 Creating High-Quality Results and Outcomes Necessary to Improve Chornic (CHRONIC) Care Act of 2017 S.1028 - RAISE Family Caregivers Act S. 1188/H.R.2535 - Lifespan Respite Care Reauthorization Act of 2017 S.670/H.R. 1652 - Over-the-Counter Hearing Aid Act H.R.3331 - To amend title XI of the Social Security Act to promote testing of incentive payments for behavioral health providers for adoption and use of certified electronic health record technology. S.1732 - Improving Access to Behavioral Health Information Technology Act S. 1905/ H.R.3931 - Excellence in Mental Health and Addiction Treatment Expansion Act S.1016 - CONNECT for Health Act of 2017 S.2120 - International Violence Against Women Act of 2017 S.2164/H.R.2953 - To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings. S.1334/H.R.2797 - Patient Choice and Quality Care Act of 2017 Improving Parity for Mental Health and Substance Use Disorder Coverage. Preserve ACA Essential Health Benefits, cost sharing subsidies, state waivers, and funding for navigators and assisters.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2017 · fourth_quarter · Health Issues
H.R. 1652, Over-the-Counter Hearing Aid Act of 2017 S.670, Over-the-Counter Hearing Aid Act of 2017
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · third_quarter · Health Issues
HR 1652, Over-the-Counter Hearing Aid Act of 2017; HR 2430, FDA Reauthorization Act of 2017; S. 670 Over-the-Counter Hearing Aid Act of 2017
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · third_quarter · Pharmacy
S. 204/H.R. 878 (Trickett Wendler Right to Try Act of 2017); authorizes the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law. S. 469/H.R. 1245 (Affordable and Safe Prescription Drug Importation Act); amends the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors. S. 670/H.R. 1652 (Over-the-Counter Hearing Aid Act of 2017); provides for the regulation of over-the-counter hearing aids. S. 297/H.R. 749 (Increasing Competition in Pharmaceuticals Act/Lower Drug Costs through Competition Act); amends the Federal Food, Drug, and Cosmetic Act to revise provisions regarding review and approval of generic drug applications or supplements to generic drug applications for drugs in some circumstances. S. 974 (CREATES Act of 2017); alters the market for drugs and biological products by changing the requirements for generic and biosimilar versions of drugs and biological products. General lobbying with regard to the preemption of states causes of action involving medical device and drug manufacturers. General lobbying with regard to off label promotion of pharmaceutical products. General lobbying with regard to pharmaceutical drug advertising. General lobbying with regard to pharmaceutical price-gouging. General lobbying with regard to biosimilar naming and labeling. General lobbying with regard to updating generic drug labeling responsibilities.
Client expense: $2,060,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Natl Highway Traffic Safety Administration (NHTSA), SENATE
2017 · third_quarter · Health Issues
H.R. 1652 Over-the-Counter Hearing Aid Act of 2017 S. 670 Over-the-Counter Hearing Aid Act of 2017
Client expense: $1,100,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Natl Highway Traffic Safety Administration (NHTSA), SENATE, Transportation, Dept of (DOT), U.S. Trade Representative (USTR), White House Office
2017 · third_quarter · Health Issues
Comments to HHS' Office for Human Research Protections on finalization of the rule on the Federal Policy for the Protection for Human Subjects; including: single IRB review mandate, revisions to the Common Rules informed consent requirements, and numerous other modifications. Comments to the Food and Drug Administration (FDA) Re: Docket Number FDA-2016-D-3466; Immediately in Effect Guidance Document: Conditions for Sale for Air Conduction Hearing Aids. Federal "Truth-in-Advertising" legislation; in general. Issues pertaining to scope of practice; in general. Repeal of the Affordable Care Act; in general. Comments to the Food and Drug Administration re: Docket No. FDA-2016-D-2268 for Insanitary Conditions at Compounding Facilities Comments to the Food and Drug Administration re: Docket 2014-D-1525-0358; Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application; Revised Draft Guidance For Industry. H.R.1652/S. 670, the "Over-the-Counter Hearing Aid Act of 2017," all provisions. H.R. 2430, the "FDA Reauthorization Act of 2017," provisions relating to the over-the-counter sale of hearing aids. Comments to the Federal Trade Commission Re: Notice of Workshop and Requesting Public Comments; Hearing Health and Technology - Workshop, Project No. P171200. Concerns regarding the potential impact of a revised United States Pharmacopeia (USP) Chapter 797 on physician practices and patient access to critical sterile drug products. H.R.1628 - American Health Care Act of 2017; in general. The "Better Care Reconciliation Act"; in general. Support for the nomination and confirmation of Jerome Adams, MD, to serve as the United States Surgeon General.
Client expense: $200,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Housing & Urban Development, Dept of (HUD), Labor, Dept of (DOL), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
2017 · third_quarter · Health Issues
Issues pertaining to the Food and Drug Administration's regulation of hearing aid devices [H.R.1652/S.670]
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · third_quarter · Health Issues
Healthcare reform; HR 1652; S 670; S 934; HR 2430
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2017 · third_quarter · Health Issues
S670 and HR1562 OTC Hearing Aid
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · third_quarter · Health Issues
Supported the Early Hearing Detection and Intervention Act (H.R. 1539, S. 562), a bill that proposes to amend the Public Health Service Act to reauthorize a program for early detection, diagnosis, and treatment regarding deaf and hard-of-hearing newborns, infants, and young children. Met with congressional offices to discuss the Over-the Counter Hearing Aid Act (S. 670, H.R. 1652)and the Medical Device User Fee Amendments (S. 934, H.R. 2430). This legislation authorizes the FDA to create a category of hearing aids available over the counter for individuals who perceive that they have mild-to-moderate hearing loss. Supported H.R. 2550, the Medicare Telehealth Parity Act which would allow audiologists to be reimbursed by Medicare for services administered via telehealth. Also, the Academy has met with congressional offices on the Access to Frontline Health Care Act (H.R. 2042). This legislation would allow for medical practitioners in certain fields to have some of their student loans covered by the Department of Health and Human Services in exchange for practicing for two years in federally-defined frontline shortage areas.
Client expense: $25,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · third_quarter · Health Issues
Alexander-Murray Health InsuranceMarketStabilization Measure Graham-Cassidy-Heller-Johnson Amendment in the nature of a substitute to HR 1628 - American Health Care Act of 2017 H.R.1628 - American Health Care Act of 2017 Better Care Reconciliation Act Discussion Draft ACA Repeal and Replace Proposals H.R. 1289 - Dorothy I. Height and Whitney M. Young, Jr., Social Work Reinvestment Act S.870 Creating High-Quality Results and Outcomes Necessary to Improve Chornic (CHRONIC) Care Act of 2017 S.1028 - RAISE Family Caregivers Act S. 1188/H.R.2535 - Lifespan Respite Care Reauthorization Act of 2017 S.670/H.R. 1652 - Over-the-Counter Hearing Aid Act Improving Parity for Mental Health and Substance Use Disorder Coverage. Preserve ACA Essential Health Benefits, cost sharing subsidies, state waivers, and funding for navigators and assisters.
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2017 · third_quarter · Health Issues
H.R. 1652, Over-the-Counter Hearing Aid Act of 2017 S.670, Over-the-Counter Hearing Aid Act of 2017
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · third_quarter · Medicare/Medicaid
Medicare Dental, Vision, and Hearing Coverage. H.R. 508, Seniors Have Eyes, Ears and Teeth Act and H.R. 3111, Medicare Dental, Vision, and Hearing Benefit Act of 2017: Proposals to expand Medicare coverage to include comprehensive coverage of dental, vision, and hearing care. Over-the-Counter Hearing Aids. S. 670/H.R. 1652, Over-the-Counter Hearing Aid Act of 2017: Proposal to provide access to more affordable hearing aids for adults with mild to moderate hearing loss. Medicare Observation Status. S. 568, H.R. 1421, Improving Access to Medicare Coverage Act of 2017: Proposal to count days in the hospital in observation status toward meeting the three-day prior hospitalization requirement for skilled nursing facility care eligibility. Medicare Buy-in. S. 1742, Medicare at 55 Act: Proposal to provide an option for any citizen or permanent resident of the United States age 55 to 64 to buy into Medicare. Medicare Buy-in and Health Care Stabilization. H.R. 3748, the Medicare Buy-In and Health Care Stabilization Act: Proposals to create a Medicare buy-in option for Americans ages 50-64, to bolster stability in the health care marketplaces with common sense solutions and to bring down costs in the health care system through innovative ways reducing waste, fraud, and abuse. Medicare Expansion. S. 1804, Medicare for All Act: Proposal to establish a Medicare-for-all national health insurance program. Medicare Privatization. (No bill.) Proposals to transform traditional Medicare into a private insurance carrier program. Medicare Eligibility Age. (No bill.) Proposal to raise the eligibility age for Medicare from 65 to 67. Affordable Care Act (ACA) Repeal and Replace. Amendments to H. R. 1628, The American Health Care Act (AHCA): Provisions affecting the costs of private health insurance for older Americans under age 65, restructuring the Medicaid program and institutional and in-home long-term care services. Medicare and Medicaid Extenders. (No bill.) Proposals to make permanent expiring funding for community-based organizations to support outreach and enrollment to low-income Medicare beneficiaries, to extend the Medicare therapy caps exceptions process and to extend and improve Medicaid home and community-based services. Alzheimers Disease Patients and Family Caregivers. (No bill.) Proposal to have the Centers for Medicare and Medicaid Services assist people living with dementia, support family caregivers, strengthen clinical practice and reduce costs to federal and state health programs. Nursing Home Residents. (No bill.) Proposal to have the Centers for Medicare and Medicaid Services maintain existing regulations protecting nursing home residents from mandatory arbitration to settle disputes with a nursing facility. Marketplace Enrollees. (No bill.) Proposal to have the Centers for Medicare and Medicaid Services extend the time for an equitable-relief opportunity for certain individuals enrolled in Marketplace plans who delayed Medicare enrollment. Affordable Care Act Patient and Consumer Protections. (No bill.) Proposal to have the Department of Health and Human Services implement the final rule on Section 1557 which protects against discrimination based on age, race, color, national origin, limited English proficiency, disability or sex. Drug Pricing. S. 1131, H.R. 2439, Fair Drug Pricing Act: Proposal to require drug manufacturers to submit price justifications when increasing the cost of drugs by 10 percent or more a year. Drug Pricing. S. 771, Access to Affordable Prescription Drugs Act: Provisions to allow Medicare to negotiate prescription drugs; prohibit anti-competitive behavior between brand and generic drug makers; allow the importation of prescription drugs from licensed Canadian pharmacies. Drug Pricing. S. 469/H.R. 1245, the Affordable and Safe Prescription Drug Importation Act: Proposal to permit wholesalers, licensed pharmacists and individuals to import drugs from Canada. Drug Pricing. S. 348, the Prescription Drug and Health Improvement Act of 2017: Provisions directing the Secretary of Health and Human Services to negotiate prices for specialty drugs, drugs that account for high levels of spending, and those with dramatic price spikes. Drug Pricing. S. 974/H.R. 2212, the Creating and Restoring Equal Access to Equivalent Samples Act of 2017: Proposal to create a civil cause of action against manufacturers who abuse the Risk Evaluation and Mitigation Strategy (REMS) process by limiting access to samples generic makers need to produce drugs and create competition. Caregiving. S. 1028, RAISE Family Caregivers Act. Proposal to require the Secretary of Health and Human Services to develop a strategy to support family caregivers.
Client expense: $220,000 · Firm income: Not reported
Government targets: Administration on Aging, Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Economic Council (NEC), Office of Management & Budget (OMB), President of the U.S., SENATE, Social Security Administration (SSA), Treasury, Dept of, Vice President of the U.S.
2017 · third_quarter · Health Issues
Regulation of hearing aids; S. 670; H.R. 1652.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · third_quarter · Health Issues
Issues related to the Over-The-Counter Hearing Aid Act, S. 670 and H.R. 1652
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · third_quarter · Health Issues
Over the counter hearing aids, including S. 670/H.R. 1652, the Over the Counter Hearing Aid Act of 2017 FDA Reauthorization bill, S. 934/H.R. 2430
Client expense: $20,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2017 · second_quarter · Health Issues
H.R. 1652 Over-the-Counter Hearing Aid Act of 2017 S. 670 Over-the-Counter Hearing Aid Act of 2017
Client expense: $1,700,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Natl Highway Traffic Safety Administration (NHTSA), SENATE, Transportation, Dept of (DOT), U.S. Trade Representative (USTR), White House Office
2017 · second_quarter · Health Issues
Comments to HHS' Office for Human Research Protections on finalization of the rule on the Federal Policy for the Protection for Human Subjects; including: single IRB review mandate, revisions to the Common Rules informed consent requirements, and numerous other modifications. Comments to the Food and Drug Administration (FDA) Re: Docket Number FDA-2016-D-3466; Immediately in Effect Guidance Document: Conditions for Sale for Air Conduction Hearing Aids. Federal "Truth-in-Advertising" legislation; in general. Issues pertaining to scope of practice; in general. Repeal of the Affordable Care Act; in general. Comments to the Food and Drug Administration re: Docket No. FDA-2016-D-2268 for Insanitary Conditions at Compounding Facilities Comments to the Food and Drug Administration re: Docket 2014-D-1525-0358; Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application; Revised Draft Guidance For Industry. H.R.1652/S. 670, the "Over-the-Counter Hearing Aid Act of 2017," all provisions. H.R. 2430, the "FDA Reauthorization Act of 2017," provisions relating to the over-the-counter sale of hearing aids. Comments to the Federal Trade Commission Re: Notice of Workshop and Requesting Public Comments; Hearing Health and Technology - Workshop, Project No. P171200.
Client expense: $210,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Housing & Urban Development, Dept of (HUD), Labor, Dept of (DOL), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
2017 · second_quarter · Health Issues
HR 1652, Over-the-Counter Hearing Aid Act of 2017; HR 2430, FDA Reauthorization Act of 2017; S. 670 Over-the-Counter Hearing Aid Act of 2017
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · second_quarter · Health Issues
H.R. 1651, the National Nurse Act of 2017 H.R. 1628, the American Health Care Act of 2017 and specifically cost sharing subsidies H.R. 1628, The Better Care Reconciliation Act S.670, Over-the-Counter Hearing Aid Act H.R.1776, Improving Access to Affordable Prescription Drugs Act H.R.817, End Surprise Billing Act S.1063, Nurse Staffing Standards for Hospital Patient Safety and Quality Care Act H.R. 2430, FDA Reauthorization Act of 2017 S.1441, Community Health Center and Primary Care Workforce Expansion Act.
Client expense: $417,905 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
2017 · second_quarter · Health Issues
H.R. 1652 Over-the-Counter Hearing Aid Act of 2017 S. 670 Over-the-Counter Hearing Aid Act of 2017
Client expense: $1,700,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Natl Highway Traffic Safety Administration (NHTSA), SENATE, Transportation, Dept of (DOT), U.S. Trade Representative (USTR), White House Office
2017 · second_quarter · Health Issues
Issues related to over the counter sale of hearing aids. Over the counter hearing aid act HR1652 & S670.
Client expense: Not reported · Firm income: $155,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · second_quarter · Consumer Issues/Safety/Products
Issues related to over the counter sale of hearing aids. Over the counter hearing aid act HR1652 & S670.
Client expense: Not reported · Firm income: $155,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · second_quarter · Health Issues
H.R.372, Competitive Health Insurance Reform Act of 2017 H.R.1215, Protecting Access to Care Act of 2017 H.R.2164, Medical Device Safety Act H.R.1652/S.670, Over-the-Counter Hearing Aid Act of 2017 S.41, Medicare Prescription Drug Price Negotiation Act of 2017 S.178, Elder Abuse Prevention and Prosecution Act S.934, FDA Reauthorization Act of 2017 Issues related to the repeal of the Patient Protection and Affordable Care Act of 2010 (P.L. 111-148) Issues related to over-the-counter hearing aids Issues related to patient safety and antibiotic resistance Issues related to off label drugs and device marketing
Client expense: $100,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Consumer Financial Protection Bureau (CFPB), Consumer Product Safety Commission (CPSC), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Transportation, Dept of (DOT)
2017 · second_quarter · Health Issues
Regulation of hearing aids; S. 670; H.R. 1652.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · second_quarter · Health Issues
S670 and HR1562 OTC Hearing Aid
Client expense: Not reported · Firm income: $130,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · second_quarter · Health Issues
1. Patient Protection and Affordable Health Care Act, implementation of provisions regarding high risk insurance pools, implementation of state based health exchanges, eligibility for health insurance premium subsidies 2. Proposals to repeal the Patient Protection and Affordable Health Care Act 3. H.R. 1628, American Health Care Act of 2017,entire bill 4. S. 670, Over-the-Counter Hearing Aid Act of 2017, entire bill 5. H.R. 2465, Steve Gleason Enduring Voices Act of 2017, entire bill 6. Stabilization of Affordable Care Act insurance marketplaces 7. S. 569, Affordable Safe Prescription Drug Importation Act of 2017, entire bill 8. H.R. 1245, Affordable Safe Prescription Drug Importation Act of 2017, entire bill
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Pension Benefit Guaranty Corporation (PBGC), SENATE
2017 · second_quarter · Health Issues
Healthcare reform; HR 1652; S 670; S 934; HR 2430
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2017 · second_quarter · Pharmacy
S. 204/H.R. 878 (Trickett Wendler Right to Try Act of 2017); authorizes the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law. S. 469/H.R. 1245 (Affordable and Safe Prescription Drug Importation Act); amends the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors. S. 670/H.R. 1652 (Over-the-Counter Hearing Aid Act of 2017); provides for the regulation of over-the-counter hearing aids. S. 297/H.R. 749 (Increasing Competition in Pharmaceuticals Act/Lower Drug Costs through Competition Act); amends the Federal Food, Drug, and Cosmetic Act to revise provisions regarding review and approval of generic drug applications or supplements to generic drug applications for drugs in some circumstances. General Lobbying with regard to the preemption of states causes of action involving medical device and drug manufacturers. General lobbying with regard to off label promotion of pharmaceutical products. General lobbying with regard to pharmaceutical drug advertising. General lobbying with regard to pharmaceutical price-gouging. Lobbying with regard to biosimilar naming and labeling. Lobbying with regard to updating generic drug labeling responsibilities.
Client expense: $1,940,000 · Firm income: Not reported
Government targets: Consumer Financial Protection Bureau (CFPB), HOUSE OF REPRESENTATIVES, SENATE
2017 · second_quarter · Health Issues
Issues pertaining to the Food and Drug Administration's regulation of hearing aid devices [H.R.1652/S.670]
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE